Onconetix, Inc. (ONCO)

↓ Download CSV

CIK 0001782107 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Onconetix, Inc. reported revenue of $815.4K, down 67.7% from the prior year. The company ran a net loss, with a net margin of -1721.0% and a gross margin of 77.6%. It held $24.93M in total assets against $9.16M in total liabilities.

Key ratios (FY2025)

77.6%
Gross margin
-2190.0%
Operating margin
-1721.0%
Net margin
-89.0%
Return on equity
-67.7%
Revenue growth (YoY)
Metric (FY)20252024202320222021
Revenue$815.4K$2.52M$58.5K
Cost of Revenue$182.5K$1.47M$1.19M
Gross Profit$632.9K$1.06M-$1.13M
Operating Income-$17.86M-$56.49M-$36.03M-$13.48M-$3.42M
Net Income-$14.03M-$58.69M-$37.41M-$13.42M-$3.42M
EPS (Diluted)$-16.56$-1823.39$-87.45$-1.10$-1.26
Total Assets$24.93M$28.18M$87.52M$26.31M$3.08M
Total Liabilities$9.16M$18.57M$21.88M$3.92M$1.64M
Shareholders' Equity$15.76M$8.54M$1.40M$22.39M$1.45M
Cash & Equivalents$25.75M$1.93M
Operating Cash Flow-$9.68M-$10.50M-$13.58M-$8.68M-$2.04M
Capital Expenditures$28.5K$3.3K$9.3K$1.9K
Shares Outstanding1.56M138.3K558.1K15.27M3.20M
Dividends Per Share$1.23